Treatment of cystic hygroma in a young infant through multidisciplinary approach involving sirolimus, sclerotherapy, and debulking surgery  by Azouz, Haya et al.
CASE REPORTTreatment of cystic hygroma in a young
infant through multidisciplinary
approach involving sirolimus, sclerotherapy,
and debulking surgery
Haya Azouz,a Haneen Salah,a Saad Al-Ajlan, MD,b and Mohammad Badran, MDc
Riyadh, Saudi ArabiaFrom
an
Fund
Confl
This c
An
Corre
of
Re
ed
350Key words: cystic hygroma; reduction; sclerotherapy; sirolimus.Abbreviations used:
CH: cystic hygromas
EXIT: extrauterine intrapartum airway
intervention
MRI: magnetic resonance imaging
mTOR: mammalian target of rapamycinINTRODUCTION
Cystic hygromas are macrocystic lymphatic mal-
formations that develop during the sixth gestational
week.1,2 Cystic hygromas (CH) mostly present in
the neck and comprise 20% to 25% of cervical
lymphatic tumors. Mainstay treatment of CH involves
complete surgical resection and sclerotherapy.
Sclerotherapy has been consistently chosen over
the other modalities. Oosthuizen et al3 reported a
management algorithm that incorporated sclerother-
apy and surgery in the management of cervicofacial
lymphatic malformation. Sclerotherapy has been
consistently employed in the management of
lymphatic malformations with notable reduction
(30%) and sometimes complete eradication of
cystic hygrma.4 Intralesional bleomycin helped
achieve complete clinical remission in 47% of
patients, greater than 50% reduction in 35.8%, and
less than 50% reduction in 17.1% in a 70-patient trial.5
However, sclerotherapy has many adverse
effects including swelling at the site of the lesion,
scarring, pulmonary fibrosis, hemorrhage, and
infection.6 Additionally, sclerotherapy may be
futile in the management of cysts not accessible
for injections. Therefore, we propose a more
effective approach that involves combining sirolimus
to the aforementioned modalities. Sirolimus inhibits
mammalian target of rapamycin (mTOR).7-9
Specifically, sirolimus binds to FK506 to form a
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u.sa.in dephosphorylation and deactivation of p70S6
kinase, which, in turn, results in the decrease of
vascular endothelial growth factor C, a stimulant of
lymphatic endothelial cells.10 Blatt et al11 reported
the first successful use of sirolimus in the manage-
ment of kaposiform hemangioendothelioma.
Herein, we present remarkable reduction of
extensive cystic hygroma in a 15-month-old infant
through a debulking surgery followed by the admin-
istration of sirolimus in addition to reduced course of
sclerotherapy.
CASE REPORT
An 8-month-old boy was hospitalized since his
birth for extensive cystic hygroma. The mother is a
47-year-old healthy woman. She is gravida 9, para 6,
plus 2 with no consanguinity, no chronic disease in
the family, and no history of congenital anomalies.
Her pregnancy was unremarkable with regular
follow ups until the antenatal presentation of an
enormous neck mass and polyhydramnios during
the 27th gestational week. She went into labor inJAAD Case Reports 2016;2:350-3.
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Fig 1. MRI of the face before treatment 2 days after birth.
Axial T2 image with fat suppression shows numerous large
bright cysts with fluid-fluid level indicating hemorrhage in
the cysts. This extends through all tissues from skin on one
side to the skin on the other side. The malformation
volume was about 370 mL. Axial T1 image at the level of
the airway confirms high signal indicating blood in the
cysts.
Fig 2. Patient at birth with large cystic hygroma involving
neck and tongue.
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section and along with extrauterine intrapartum
airway intervention (EXIT) due to extensive neonatal
neck mass that would potentially compromise the
neonate’s airway. The EXIT procedure is usually
done for any fetus with a large neck mass before
cutting the umbilical cord.
The patient exhibited no dysmorphism, with the
large neck mass mainly involving the right side of the
neck. His tongue was also involved, posing a
challenge for conventional treatment with sclero-
therapy. His chest, abdomen, cardiac, genitalia, and
back were unremarkable. The birth weight was
3.08 kg. Baseline magnetic resonance imaging
(MRI) (Fig 1) done 2 days after his birth showed a
mass with a volume of 370 mL. The diagnosis was
cystic hygroma.
The patient underwent 4 sclerotherapy sessions
with a 1-week period between sessions a week after
his birth. The sclerosing agents used include alcohol,
polidocanol, and doxycycline. He then underwent
debulking surgery for the cystic hygroma and
gastrostomy to facilitate the administration of
sirolimus. Subsequently, he underwent one more
sclerotherapy session for a total of 5 sclerotherapy
sessions. The cystic hygroma persisted and the veins
within the tumor became sclerosed and hence
difficult for injection; therefore, sclerotherapy was
no longer an option for management. He was then
started on sirolimus when he was 1 month old withan initial dose of 0.07 mg/kg given twice daily
through gastrostomy tube. Sirolimus level was
monitored and maintained within a range of
(0.004e0.01 mg/kg). Ten days after starting siroli-
mus, MRI showed visual 70% to 80% improvement
(about 74e110 mL). Follow-up ultrasound scans
showed a decrease in the cystic components of the
hygroma mass. After the administration of sirolimus
for 15months, the size of the tumor decreased to 90%
of its original size before treatment, leaving a residual
of 10 to 20 mL with a 79- to 110-mL reduction of
original volume of 370 mL of cysts that were in the
cheek, temple, and tongue that were not treated with
sirolimus (Figs 1-8). The patient had laryngomalacia
because of the mass effect of the cystic hygroma that
compromised the airway. He is a potential candidate
for future plastic surgeries to remove redundant skin.DISCUSSION
Cystic hygromas may potentially present any-
where in the body. Some of the common sites
include the cervicofacial region (80% of cases),
mediastinum, beneath the tongue, axilla, and groin.
Sixty percent of CH present congenitally.6
Management of CH ideally is through surgical
resection or sclerotherapy.6 A more recent manage-
ment option is an antiproliferative agent:
Sirolimus.9,12,13 Sirolimus (rapamycin) is an mTOR
inhibitor that has a less drastic adverse effect profile
than the preceding management modalities. It in-
hibits mTOR, which plays an integral role in several
signaling cascades that involve cellular motility,
angiogenesis, and cell growth.10,13 Because mTOR
is the final common pathway mediating most
vascular tumors, sirolimus is an important target to
treat lymphangiomas and hemangiomas.8-10,13
Pharmacokinetics associated with sirolimus varies
considerably because of itsmetabolismby cytochrome
P450 enzymes, thereby depending on the maturation
of these microsomal enzymes in young infants and
Fig 3. Patient after 2 sclerotherapies at 28 days of age with
regression in the size of the cystic hygroma.
Fig 4. Patient after surgical debulking at 45 days of age
along with prior 2 sclerotherapy sessions but no sirolimus
yet.
Fig 5. Three months later, the patient after starting
sirolimus.
Fig 6. Patient 8 months after starting sirolimus with
remarkable reduction in the size of the cystic hygroma.
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CYP3A5, and CYP2C8 are the most commonly
implicated in sirolimus clearance with 95% of
metabolism carried out by CYP3A.13
Several recent studies discovered the successful
use of sirolimus in treating vascular anomalies.8,12
Tschauner et al12 reported a case series of 4 female
patients being treated for cystic lymphangioma with
sirolimus. Patients’ ages ranged between 6 months
and 3 years. The maximum reduction in tumor size
reported was 75%, whereas the reduction in size of
the mass in this patient is 90%. A similar case series
was conducted by Lackner et al7 in which children
with Kaposiform hemangioendothelioma (KHE),combined lymphatic-venous malformations, and
orbital lymphangioma were treated with sirolimus;
end results of sirolimus were reported in terms of
clinical improvement rather than by reduction in the
size of the lesions.7
Rationale for administering sirolimus in this case is
extensive size of the cystic hygroma. Sclerotherapy
doses depend on the body weight, so it is not
possible to completely eradicate a large tumor in
an infant. Sclerotherapy targets specific cysts in each
session necessitating a minimum of 2 sessions for
every cyst. Additionally, the lymphatic malformation
in this case was not limited to superficial neck
Fig 7. Patient after 15 months of sirolimus therapy with
notable reduction in cystic hygroma.
Fig 8. MRI of the face after sirolimus treatment for
10 months: The estimated residual volume is about 10 to
30 mL. Notably, there is resolution of untreated areas in the
tongue and cheeks.
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including the tongue, which is not feasible to be
approached by sclerotherapy. Interestingly, the
tongue, temples, and cheek showed remarkable
reduction in size after sirolimus administration.
Although this patient received both sclerotherapy
and sirolimus, the sclerotherapy was administered
for a reduced course with the considerable reductionin size occurring 10 weeks after the last sclerother-
apy, whereas the reduction in size in response
to sclerotherapy is anticipated to occur within
6 weeks from administration. We suggest that there
is a synergistic effect between sclerotherapy and
sirolimus.CONCLUSION
Sirolimus is a novel therapy for vascular anoma-
lies. A multidisciplinary approach that involves
administering sirolimus and sclerotherapy in addi-
tion to a debulking surgery is likely to improve the
outcome in patients with cervicofacial lymphatic
malformations. However, further studies on larger
groups should be conducted to standardize this
management approach.
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